| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 139.4 | 100.1 |
| Profit before tax | 10.7 | 1.7 |
| Net income | 19.3 | 1.7 |
| EPS (diluted, $ a share) | $0.35 | $0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +1051.8% |
|---|---|
| Revenue, year on year | +39.3% |
| Operating margin | 5.8% |
10-Q filed with the SEC, NASDAQ: CDNA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
CareDx, Inc.: key numbers
- Share price
- $73.72Close, Nov 16
- Market cap
- $3.87B
- Shares outstanding
- 52.54MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from CareDx, Inc.
All →CareDx Director Michael Goldberg Sells $1.09M of Stock
Michael Goldberg, Director, sold 13,800 shares of CareDx, Inc. at $78.32 to $79.85 a share (average $79.15) in 3 transactions, worth $1.09M in total on Nov 12, 2026. Shares held after the trade: 48,526 (-4.4%).
- Value
- $1.09M
- Shares
- 13,800
- Average price
- $79.15
- Role
- Director
- Holding change
- -4.4%
- Trade date
- Nov 12, 2026
CareDx CFO & COO Keith Kennedy Sells $166K of Stock
Keith Kennedy, CFO & COO, sold 2,097 shares of CareDx, Inc. at $78.78 to $79.61 a share (average $79.29) in 2 transactions, worth $166K in total on Nov 12, 2026. Shares held after the trade: 199,147 (-0.6%).
- Value
- $166K
- Shares
- 2,097
- Average price
- $79.29
- Role
- CFO & COO
- Holding change
- -0.6%
- Trade date
- Nov 12, 2026
CareDx Secretary and General Counsel Jeffrey Adam Novack Sells $332K of Stock
Jeffrey Adam Novack, Secretary and General Counsel, sold 4,096 shares of CareDx, Inc. at $80.47 to $83.33 a share (average $81.13) in 3 transactions, worth $332K in total on Nov 10, 2026. Shares held after the trade: 96,604 (-0.9%).
- Value
- $332K
- Shares
- 4,096
- Average price
- $81.13
- Role
- Secretary and General Counsel
- Holding change
- -0.9%
- Trade date
- Nov 10, 2026
CareDx CFO & COO Keith Kennedy Sells $4.82M of Stock
Keith Kennedy, CFO & COO, sold 61,961 shares of CareDx, Inc. at $76.55 to $83.60 a share (average $77.82) in 8 transactions, worth $4.82M in total on Nov 5, 2026. Shares held after the trade: 199,147 (-0.3%).
- Value
- $4.82M
- Shares
- 61,961
- Average price
- $77.82
- Role
- CFO & COO
- Holding change
- -0.3%
- Trade date
- Nov 5, 2026
CareDx Financial Results
CareDx reported third quarter 2026 revenue of $139 million, a 39% year-over-year increase driven by strong growth in Testing Services. The company achieved GAAP net income of $19 million and raised its full-year 2026 revenue guidance to a range of $520 million to $530 million.
“We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy.”
John Hanna, President and Chief Executive Officer of CareDx
“We see significant clinical interest in how molecular information can inform more decisions across a patient’s care journey, while continuing to make our solutions easier for providers to adopt and patients to access. We believe these dynamics create meaningful opportunities for continued profitable growth.”
John Hanna, President and Chief Executive Officer of CareDx
CareDx M&A Deal with Naveris, Inc.
CareDx, Inc. filed an amendment to its original 8-K to provide required historical financial statements and pro forma financial information regarding its completed acquisition of Naveris, Inc. The acquisition was originally reported as completed on July 7, 2026. The filing includes audited financial statements for Naveris for the year 2025 and unaudited figures for the first quarter of 2026.
- Counterparty
- Naveris, Inc.